Genetic Inhibition of CaMKII in Dorsal Striatal Medium Spiny Neurons Reduces Functional Excitatory Synapses and Enhances Intrinsic Excitability

Jason R. Klug¹, Brian N. Mathur⁶, Thomas L. Kash¹²³, Hui-Dong Wang⁴, Robert T. Matthews¹³, A. J. Robison¹²⁵, Mark E. Anderson⁷, Ariel Y. Deutch¹²³⁴⁵, David M. Lovinger⁶, Roger J. Colbran¹²³, Danny G. Winder¹²³

¹ Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America, ² Center for Molecular Neuroscience, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America, ³ J.F. Kennedy Center for Research on Human Development, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America, ⁴ Department of Psychiatry, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America, ⁵ Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America, ⁶ Laboratory for Integrative Neuroscience, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Rockville, Maryland, United States of America, ⁷ Departments of Internal Medicine and Molecular Physiology and Biophysics, University of Iowa, Iowa City, Iowa, United States of America

Abstract

Ca²⁺/calmodulin-dependent protein kinase II (CaMKII) is abundant in striatal medium spiny neurons (MSNs). CaMKII is dynamically regulated by changes in dopamine signaling, as occurs in Parkinson’s disease as well as addiction. Although CaMKII has been extensively studied in the hippocampus where it regulates excitatory synaptic transmission, relatively little is known about how it modulates neuronal function in the striatum. Therefore, we examined the impact of selectively overexpressing an EGFP-fused CaMKII inhibitory peptide (EAC3I) in striatal medium spiny neurons (MSNs) using a novel transgenic mouse model. EAC3I-expressing cells exhibited markedly decreased excitatory transmission, indicated by a decrease in the frequency of spontaneous excitatory postsynaptic currents (sEPSCs). This decrease was not accompanied by changes in the probability of release, levels of glutamate at the synapse, or changes in dendritic spine density. CaMKII regulation of the AMPA receptor subunit GluA1 is a major means by which the kinase regulates neuronal function in the hippocampus. We found that the decrease in striatal excitatory transmission seen in the EAC3I mice is mimicked by deletion of GluA1. Further, while CaMKII inhibition decreased excitatory transmission onto MSNs, it increased their intrinsic excitability. These data suggest that CaMKII plays a critical role in setting the excitability rheostat of striatal MSNs by coordinating excitatory synaptic drive and the resulting depolarization response.

Introduction

The striatum is the major input nucleus of the basal ganglia [1]. Dysfunction in this region is associated with drug addiction, Parkinson’s disease and other disorders [2,3,4,5,6,7,8]. The striatum is primarily composed of projection GABAergic medium spiny neurons (MSNs) that integrate glutamatergic excitatory transmission with modulatory dopaminergic transmission. Since MSN firing is thought to be driven primarily by excitatory drive, understanding the basic mechanisms of glutamatergic transmission onto MSNs is necessary to understand how the striatum functions in health and disease.

Calcium-calmodulin-dependent kinase II (CaMKII) is a Ser/Thr kinase that is highly expressed in the striatum, constituting ~0.7% of total striatal protein [9]. CaMKII assemblies into dodecameric complexes that in the striatum predominantly contain CaMKIIα and CaMKIIβ isoforms [10]. As a major constituent of the postsynaptic density (PSD) in the dorsal striatum [11] as well as other forebrain regions [12,13], CaMKII is activated by N-methyl-D-aspartate-receptor (NMDAR)-mediated calcium influx [14,15,16]. CaMKII is a key modulator of hippocampal and cortical pyramidal cell glutamate synapse function [17,18,19]. CaMKII can phosphorylate many downstream substrates including the ionotropic glutamate receptors NMDARs and α-amino-3-hydroxy-5-methyl-4-isoxazolopropionic acid receptors (AMPARs) [20,21,22,23,24,25]. Indeed, in hippocampal pyramidal cells, CaMKII activation enhances synaptic trafficking of AMPARs and channel function [26,27,28,29]. In addition, a constitutively active form of CaMKII can decrease...
intrinsic excitability of hippocampal neurons as well as MSNs in the nucleus accumbens shell [30,31]. While much is known about the role of CaMKII at glutamate synapses on glutamatergic projection neurons such as hippocampal and cortical pyramidal neurons, relatively little is known for GABAergic cells. Indeed, little CaMKII is expressed in GABAergic interneurons [32,33,34], making GABAergic projection cells such as MSNs, which are highly enriched in CaMKII, unique targets for studying the role of CaMKII in synaptic transmission and intrinsic excitability.

Previous studies have implicated striatal CaMKII in Parkinson’s disease (PD) and addiction. CaMKII is hyperactivated after striatal dopamine depletion, and CaMKII inhibition rescued striatal synaptic plasticity and motor deficits found in animal models of Parkinson’s disease [33]. Striatal CaMKII regulates motivational effects of reward cues on goal-directed behaviors [36] as well as curbing D1R-mediated cocaine hyperlocomotion [37] and modulating excitability following chronic cocaine administration [31]. Thus, a better understanding of CaMKII’s role in striatal glutamatergic synaptic transmission may suggest new approaches to treat PD and addiction.

In addition to its postsynaptic roles, CaMKII modulates a variety of presynaptic functions, including trafficking of synaptic vesicles [38,39,40,41,42], P/Q type calcium channels [43,44,45], voltage-gated sodium channels [46,47], catecholamine synthesis [48,49] and dopamine transporter function [50,51]. Thus, an investigation of the role of CaMKII within striatal MSNs requires a cell-specific approach. To accomplish this, we generated a transgenic mouse line that expresses a CaMKII inhibitory peptide selectively within dorsal striatal MSNs. Using this line, we found that CaMKII inhibition in dorsal striatal MSNs leads to a loss of functional glutamatergic synapses and an increase in intrinsic excitability. These findings shed light on the neural mechanisms underlying the development of striatal neural circuits, learning and memory, and motor behavior.

Materials and Methods

Generation of EAC3I-4 transgenic mice

For generation of double transgenic EAC3I-4 x tTA animals, heterozygous transgenic mice carrying the tTA gene driven by an alpha CaMKII promoter fragment were bred to heterozygous mice carrying the EAC3I transgene fused to EGFP driven by the tetO promoter. The CaMKII-tTA mice were obtained from Dr. Eric Kandel’s lab and maintained at Vanderbilt University. The autocamtide-3 derived inhibitory peptide (EAC3I) sequence (KKALHRQEAVDAL) mimics the autoinhibitory region of the CaMKII regulatory domain (residues 278–290) and acts by competitively binding to the catalytic site. In *in vitro* biochemical assays AC3-I blocks the phosphorylation of an autocamtide-2 substrate by purified rat CaM kinase with an IC50 of 3 μM [52,53], with a ≥100-fold reduced potency toward protein kinase C, CaM kinase I or CaM kinase IV [52,54,55]. EAC3-I is made up of the AC3-I peptide fused N-terminal to enhanced green fluorescent protein (EGFP) to stabilize and mark cellular and tissue distribution. In a previous study, EAC3I was transgenically expressed in the heart and total CaMKII activity in extracts was reduced by ≈40% [56]. This level of inhibition is likely to be a substantial underestimate of *in vivo* inhibition, because proteins were diluted upon homogenization due to mosaic transgene expression.

We quantified the level of mosaicism in our EAC3-I mouse by staining with a NeuN antibody (1:1000, Millipore) to label all neurons (See supplemental for detailed immunohistochemical labeling). Manual counts of the number of EGFP positive neurons versus total number of NeuN stained neurons in 2-stacks in the dorsal lateral striatum were made in MetaMorph (Molecular Devices; Sunny Vale, CA), providing an estimate of the percent of cells expressing the transgene. TetO-linked transgene expression is controlled using mouse chow containing 200 mg/kg Doxycycline (DOX; Bio-Serv; Frenchtown, NJ). For DOX rescue experiments pregnant dams were fed DOX and weaned pups continued with the same food. At 6 weeks DOX was removed and the transgene was allowed to be expressed for 4–5 weeks. All DOX recordings were made between 10–11 weeks. All mice had been inbred onto a C57BL/6 background for more than seven generations. Gha1 knockout mice (Andrew Holmes Lab) and wildtype littersmates 8–16 weeks of age were utilized [57].

Brain Slice Preparation

All procedures were performed in accordance with the Vanderbilt University Institutional Animal Care and Use Committee and National Institutes of Health Guide for Care and Use of Laboratory Animals and approved by the Vanderbilt and NIAAA Animal Care and Use Committee. Male and female EAC3I-4 transgenic mice or littermate controls (9–13 weeks or 3–4 weeks animals when indicated) were decapitated under anesthesia (Isoflurane). The brains were quickly removed and placed in ice-cold sucrose-artificial cerebrospinal fluid (ACSF): (in mM) 194 sucrose, 20 NaCl, 4.4 KCl, 2 CaCl2, 1 MgCl2, 1.2 NaH2PO4, 10.0 glucose, and 26.0 NaHCO3 saturated with 95% O2-5% CO2. Hemisected coronal slices 300 μm in thickness were prepared using a Tissue Slicer (Leica). Slices containing dorsal lateral striatum were collected rostral to the crossing of the anterior commissure (Bregma 1.10–0.2 mm) [Franklin and Paxinos 1997]. Slices were then stored in a heated (approximately 28°C), oxygenated (95% O2-5% CO2) holding chamber containing normal ACSF (ACSF; [in mM] 124 NaCl, 4.4 KCl, 2 CaCl2, 1.2 MgSO4, 1 NaH2PO4, 10.0 glucose, and 26.0 NaHCO3) for 1 hour and then transferred to a submersion-type recording chamber (Warner Instruments) where they were superfused with heated (30°C) oxygenated ACSF at a rate of about 2–3 ml/min. Preparation of Gha1KO animals and controls brain slices used very similar methodology except the high sucrose ACSF contained (in mM); 194 sucrose, 30 NaCl, 4.5 KCl, 1 MgCl2, 26 NaHCO3, 1.2 NaH2PO4, and 10 glucose and 250 μm thick brain slices were placed in 30°C oxygenated ACSF containing (in mM); 124 NaCl, 4.5 KCl, 2 CaCl2, 1 MgCl2, 26 NaHCO3, 1.2 NaH2PO4, and 10 glucose for 30 minutes followed by 30 minutes at room temperature before moving hemissections to the recording chamber.

Whole-Cell Voltage Clamp Recordings

MSNs of the dorsal lateral striatum were directly visualized with infrared video microscopy (Olympus BX51WI with QImaging Rolera-XP Camera). Only highly expressing EGFP-containing MSNs were selected for study and compared to neighboring MSNs visually devoid of EGFP expression. Recording electrodes (3–6 MΩ) were pulled on Flaming-Brown Micropipette Puller (Sutter Instruments) using thin-walled borosilicate glass capillaries (WP). EPSCs were evoked by local fiber stimulation with bipolar nichrome electrodes. Stimulating electrodes were placed on the border of the corpus callosum and dorsal lateral striatum 100–300 μm dorsal to the recorded neuron, and electrical stimulation (5–20 V with 100–150 μs duration, Grass Instruments) was applied at 0.05 Hz unless otherwise noted. This location most likely stimulates both cortical and thalamic glutamatergic axons onto MSNs. Recording electrodes (3–6 MΩ) were filled with [in mM] Cs+ gluconate (117), HEPES (20), EGTA (0.4), TEA (5), MgCl2 (2), ATP (4), GTP (0.3) pH 7.35, 283–290 mOsm. Series
resistance averaging 16 MΩ (ranging 8–30 MΩ) was monitored and experiments with changes greater than 20% were omitted. AMPAR EPSCs and sEPSCs were isolated by adding 25 μM picrotoxin and recording at a holding potential of −70 mV in normal ACSF. To isolate mEPSCs 1 μM TTX was added in addition to sEPSCs recording conditions. In all experiments a time period of at least 5 minutes post break-in was allowed for internal solution exchange and stabilization of membrane properties. GluA1KO sEPSC recordings were conducted similarly except recording ACSF contained 50 GluA1KO sEPSC recordings were conducted similarly except solution exchange and stabilization of membrane properties. A period of at least 5 minutes post break-in was allowed for internal normal ACSF. To isolate mEPSCs 1 μM TTX was added in picrotoxin and recording at a holding potential of −70 mV

Whole cell current clamp recordings

Slices were prepared as before, but perfused with ACSF containing (in mM): NaCl (124), NaH₂PO₄ (1.25), KCl (2.5), CaCl₂ (2.5), MgSO₄ (1.1), NaHCO₃ (26), Glucose (11) pH = 7.35, 300–305 mOsm. Recording electrodes were filled with (in mM): K⁺ glutamate (120), NaCl (4), HEPES (10), Mg-ATP (4), Na-GTP (0.3), KCl (20), Na⁺ Phosphocreatine (10) pH = 7.3, 285–290 mOsm. MSNs were identified by their intrinsic membrane properties (i.e. resting membrane typically more negative than −30 mV, inward and outward rectification in response to somatic positive and negative current injections, and a long depolarizing ramp to delayed first spike discharge [30]. Recordings were rejected if the initial Vm was more positive than −75 mV. Resting membrane potential or zero current potential was determined right upon break-in. Spontaneous excitatory postsynaptic potentials after 5 minutes post break-in were recorded for 4 minutes with the cell dynamically current clamped at −85 mV. Resting membrane potential was monitored and current was injected to maintain the resting potential at −85 mV. For current-voltage (IV) relationships positive or negative current injections were given in 20 pA steps until the cell reached threshold and fired a single AP. Five additional current injections steps (20 pA each) were given above threshold. Input resistance was monitored throughout the experiment and the cell was rejected if the input resistance changed by more than 20%. Healthy cells showed APs that crossed +30 mV and stable resting membrane potentials.

Lucifer yellow intracellular fills, confocal imaging and measurement of dendritic structure

Transgenic EAC3I mice (3–4 months) were perfused with 10 ml room temperature phosphate buffered saline (PBS) followed by 100 ml of 4% paraformaldehyde solution delivered over 10–20 minutes. Brains were post-fixed in ice cold paraformaldehyde solution for an additional hour before 200 μm thick coronal sections of the precommissural striatum were prepared on a vibrating microtome (Leica; Buffalo Grove, IL). MSN cell bodies in dorsolateral striatum were visualized at 40×. Randomly selected EAC3I-expressing (EGFP-positive) MSNs and non-fluorescent (EGFP-negative) MSNs in the dorsal lateral striatum were iontophoretically filled with an 8% solution of Lucifer yellow (LY; Sigma-Aldrich, in 50 mM Tris-HCl, pH 7.4) using hyperpolarizing current (3–5 nA for 8–10 minutes). Slices were fixed in 4% paraformaldehyde/PBS overnight at 4°C and then coverslipped using Prolong Gold mounting solution (Invitrogen; Grand Island, NY).

Digital images of MSN dendritic segments located 80–100 μm distal to the cell soma were captured using a Zeiss LSM 710 confocal microscope with ×63 oil immersion objective and ×2.5 digital zoom. Spine density of three to four dendritic segments emanating from different primary dendrites was averaged to yield a mean spine density value per MSN. A total of 17 EAC3I-negative MSNs and 16 EAC3I-positive MSNs were analyzed; these were obtained from four different mice of each genotype. After the confocal images were coded by someone not involved in the study, another person unaware of the animal or genotype of the MSN being examined used Imaris (Version 5.5; Bitplane) to quantify dendritic spine density. A three-dimensional perspective in “surpass” mode of the software package was generated and images were processed with background subtraction thresholding and smoothed with a Gaussian filter. Dendritic segments were modeled with the largest and smallest diameters set at 2 μm and 1 μm, respectively. Florescence in each dendritic segment was thresholded manually to capture all dendritic spines. The minimum terminal point spine diameter was set at 0.143 μm and the florescence contrast threshold was set at 1. Identified spines were counted and marked in 3D on a rotating version of the image. Finally, each structure identified as a spine by the Imaris software was visually verified. In order to determine total dendritic length and generate a Sholl analysis (number of dendritic branches intersecting circular rings drawn around the soma every 20 μm distal to the soma), we used Neurolucida Explorer (MicroBright-Field; Willington, VT).
**Pharmacology**

Picrotoxin, (+)Mk-801 maleate [(S,10R)-(+)-3-Methyl-10,11-dihydro-5H-dibenzo[a,c]cyclohepten-5,10-imine maleate], NBQX (2,3-Dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-sulfonamide), (R)-Baclofen ([R]-4-Amino-3-[4-chlorophenyl]butanoic acid), and DL-APV ([DL]-2-Amino-5-phosphono pentanoic acid) were purchased from Tocris (Ellisville, Missouri). DMSO (0.05%) (Sigma-Aldrich) was used as a vehicle for picrotoxin.

**Results**

**Characterization and in vivo localization/expression of CaMKII inhibitory (EAC3I) peptide**

To determine the role CaMKII plays in modulating glutamatergic transmission onto MSNs in the dorsal lateral striatum, we generated a transgenic mouse model with striatally-enriched expression of a CaMKII inhibitory peptide fused to enhanced green fluorescent protein (EGFP) referred to hereafter as EAC3I [52]. The EAC3I peptide inhibits all isoforms of CaMKII, as well as both calcium-dependent and independent forms of the kinase, and the fusion with EGFP allows for visualization of the regional and cellular distribution of the transgenically expressed protein. EAC3I was previously utilized in another transgenic line to examine the role of CaMKII in the heart [56]. To spatially and temporally regulate EAC3I expression, the tetracycline transactivator (tTA) is driven by a CaMKII promoter fragment with the tTA gene product driving expression of EAC3I (Figure 1A).

Constitutive expression of the EAC3I transgene has no overt effect on viability or on gross brain morphology, and is silenced by including doxycycline (DOX, 200 mg/kg) in the animals’ chow for two weeks (Figure 1B). The alpha CaMKII promoter normally restricts transgene expression to the forebrain, but this founder line exhibits enrichment of EAC3I expression in the MSNs of the dorsal striatum (Figure 1C, 1D), presumably due to integration site-dependent effects. Little to no expression of the inhibitor was observed in cortex and thalamus (Figure 1C, 1D). The EAC3 peptide is expressed in a mosaic pattern throughout the dorsal striatum, with 34±4% of neurons containing the inhibitory peptide (Figure 1D). The mosaicism observed is common in transgenic animals and different founder lines utilizing the alpha CaMKII promoter fragment to drive transgene expression show differing expression patterns throughout the forebrain [59,60]. However, we observed no overlap of signal between EGFP positive neurons and striatal cholinergic and GABAergic interneuron markers such as ChAT, parvalbumin, NPY, and calretinin (Figure S1). At higher magnification the EAC3I inhibitory peptide was observed in the MSN cell soma, dendrites and dendritic spines (Figure 1E). Dense expression of EAC3I was detected in both the globus pallidus and in the substantia nigra pars reticulata (Figure 1G, 1H, 1F), but higher magnification images revealed the staining was localized to synapses (Figure 1F), demonstrating that both indirect and direct pathway MSNs contain the inhibitory peptide (Figure 1G, 1F, 1H).

**Effects of CaMKII inhibition onMSN glutamatergic inputs in dorsal lateral striatum**

We initially recorded sEPSCs from MSNs using whole-cell voltage clamp in the presence of picrotoxin to isolate excitatory transmission. In this and subsequent electrophysiological analyses, we compared three control groups of MSNs with one experimental group: Control 1) MSNs from tTA/~tetO-EAC3I~ mice (Wt), Control 2) MSNs from tTA/~tetO-EAC3I~ mice (tTA), Control 3) EGFP negative MSNs from tTA/~tetO-EAC3I~ mice (NON EGFP) and Experimental 4) EGFP positive MSNs from tTA/~tetO-EAC3I+~ mice (referred to as EAC3I MSNs (EGFP)). In adult mice no differences in sEPSC amplitudes were observed between MSNs from the four groups described above (in μA, Wt 13.39±0.81; tTA 11.98±1.27; NON EGFP 14.97±1.38; EGFP 14.78±0.67) [F (3, 33) = 1.46; p = NS; Figure 2A, 2G]. However, sEPSC frequency was markedly reduced in EAC3I MSNs relative to all control MSN groups (in Hz, Wt 3.20±0.24; tTA 2.85±0.17; NON EGFP 2.99±0.63; EGFP 1.07±0.15) [H (3, 33) = 19.85; p = 0.0002]; Figure 2A, 2D]. Similar results were observed in sEPSC frequency in 3–4 week old mice (in Hz, NON EGFP 3.94±1.03; EGFP 1.08±0.23) [U (9) = 3.000; p = 0.0341; data not shown]. Additionally, we did not observe any differences in AMPAR-mediated current voltage relationship between EAC3I-containing and lacking MSNs (Rectification Index (RI) = −70 mV/+10 mV, NON EGFP 1.97±0.18; EGFP 1.75±0.24) [t (8) = 0.575; p = 0.58; data not shown]. To determine if the decrease in sEPSC frequency was due to a change in the intrinsic electrical activity in the slice, we also examined activity-independent miniature EPSCs (mEPSCs) in the presence of TTX. Similar to the results with sEPSCs, mEPSC frequency was also reduced in EAC3I MSNs (in Hz, Wt 2.96±0.32; tTA 4.88±0.67; NON EGFP 3.89±0.41; EGFP 0.97±0.40) [F (3, 22) = 9.668; p = 0.0009]; Figure 2B, 2F], suggesting that this effect is independent of presynaptic excitability.

The use of the tTA expression system provides DOX-dependent control of EAC3I expression (Figure 1B). We suppressed expression of the transgene by supplementation of food with DOX (200 mg/kg) for both the dam and her litter until 6 weeks of age, and then recorded from EAC3I-expressing MSNs 4 weeks after removal of DOX. Under these conditions, the global expression of EAC3I was markedly lower than in non-DOX exposed mice, as has been previously noted with the tTA expression system [61]. Notably, sEPSC frequency in the EAC3I MSNs was not significantly different from controls (in Hz, Wt 2.91±0.46; tTA 2.65±0.48; NON EGFP 2.55±0.39; EGFP 2.42±0.39) [F (3, 32) = 0.2343; p = NS]; Figure 2C, 2F]. These data indicate that the sEPSC frequency phenotype observed in no-DOX EAC3I MSNs is not likely due to an insertion site artifact.

**MSN CaMKII inhibition reduces excitatory transmission independently in release probability**

The canonical interpretation of a reduction in s/mEPSC amplitudes is via a reduction in the probability of glutamate release or the number of release sites/number of synapses. In order to better understand the mechanism(s) underlying the reduction in s/mEPSC frequency in EAC3I MSNs we first examined paired-pulse ratios (PPR) of evoked EPSCs, a measurement that inversely correlates with neurotransmitter release probability [62]. The PPR of evoked EPSCs on control MSNs did not differ from that observed on EAC3I MSNs [PPR 40 ms ISI: (Wt 1.10±0.03; tTA 1.16±0.15; NON EGFP 1.20±0.10; EGFP 1.01±0.07) H (3, 33) = 2.436; p = NS; PPR 60 ms ISI: (Wt 1.12±0.07; tTA 1.17±0.16; NON EGFP 1.01±0.07; EGFP 0.94±0.06) F (3, 33) = 1.377; p = NS; Figure 3A, 3B, 3C]. To show that we could predictably manipulate PPR we used the GABA<sub>B</sub> agonist baclofen (10 μM). Baclofen acts presynaptically to reduce the probability of release and therefore increase PPR at a number of CNS synapses [62,63]. Baclofen increased the PPR in EAC3I MSNs to a similar extent as in control MSNs suggesting that release probability was modifiable in the CaMKII-inhibited cells and not at a floor (NON EGFP baseline 1.13±0.11, 10 μM baclofen 2.29±0.28, 20 min washout 1.30±0.14) [F (1, 9) = 0.5403; p = NS; Figure 3E]. Similar results
were observed with coefficient of variation (CV) measures of evoked EPSCs, where baclofen application enhanced CV to the same degree in EAC3I MSNs and controls (NON EGFP baseline 0.21 ± 0.05, 10 μM baclofen 0.56 ± 0.07, 20 min washout 0.24 ± 0.07; EGFP baseline 0.23 ± 0.05, 10 μM baclofen 0.52 ± 0.11, 20 min washout 0.31 ± 0.06) [F (1, 9) = 0.0047; p = NS; Figure 3D]. Additionally, we found that baclofen significantly decreased the sEPSC frequency to a similar extent in both EAC3I MSNs and controls (NON EGFP baseline 100 ± 22.4%, 10 μM baclofen 37.8 ± 11.1%; EGFP baseline 100 ± 33.2%, 10 μM baclofen 40.4 ± 10.2%) [F (1, 9) = 0.0025; p = NS; Figure 3F].

Changes in s/mEPSC frequency could also theoretically be produced by changes in synaptic glutamate concentration. To address this possibility, we utilized MK-801, an uncompetitive, activity-dependent and irreversible antagonist of NMDARs [64]. After obtaining a stable baseline of evoked NMDAR-mediated EPSCs at +40 mV in the presence of picrotoxin and NBQX, the
CaMKII inhibition does not alter dendritic spine density, but reduces dendritic length and complexity

We next examined dendritic spine density, dendritic length and branching complexity in CaMKII-inhibited versus neighboring non-inhibited cells. Previous work has suggested a correlation between changes in mEPSC frequency and dendritic spine density [65,66,67,68], although this is not always the case [69]. Additionally, CaMKII has been shown to modulate dendritic length in the hippocampus [70]. There was no difference in spine density related to expression of the transgene (NON EGFP 13.03±0.52 spines per 10 μm vs.; EGFP 17.95±0.85) [t (31) = 0.087; p = NS; Figure 5A, 5B]. However, we observed a significant decrease in total dendritic length (NON EGFP 1538±99 μm vs.; EGFP 1134±78) [t (31) = 3.158; p = 0.0035; Figure 5C, 5D]. Sholl analysis revealed a significant overall decrease in dendritic branching (F (1,31) = 28.55; p<0.0001), with Bonferroni post-hoc analyses revealing specific significant decreases at 40 and 60 μm distal to the cell soma (Figure 5E).

GluA1 KO mimics EAC3I decrease in sEPSC frequency

The AMPAR GluA1 subunit is critical for activity-dependent postsynaptic strengthening of excitatory synapses, and is inserted into the synaptic membrane in a CaMKII-dependent process in hippocampal neurons [26]. Mice lacking the GluA1 subunit of the AMPAR have deficits in CA1 LTP [57] (but see [71]) and deficits in learning and memory [72,73,74,75]. Additionally, reductions in CaMKIIα mRNA and protein levels are seen in the hippocampus of GluA1 KO animals [76]. If the CaMKII inhibition-dependent reduction in functional glutamatergic synapses on striatal MSNs is due to defects in synaptic GluA1 insertion, then we predicted that GluA1 knockout mice should mimic EAC3I mice in terms of sEPSC frequency and amplitude. Thus, we measured sEPSC...
Figure 3. Dorsal lateral striatum MSN CaMKII inhibition reduces excitatory transmission independently of changes in release probability. (A) (Upper trace, black) NON EGFP (EAC3I-lacking) MSN PPR (50 ms ISI) example trace baseline (average of 20 sweeps, 0.05 Hz). (Middle trace, black) EAC3I-lacking MSN PPR (50 ms ISI) example trace post 10 μM Baclofen wash in (average of 20 sweeps, 0.05 Hz). (Bottom trace, black) EAC3I-lacking MSN PPR (50 ms ISI) example trace 20 minutes post wash out of drug (average of 50 sweeps, 0.05 Hz). (B) Same as in (A), but for an EGFP (EAC3I-containing) MSN. (C) Average PPR recorded by paired-pulse stimulation eliciting EPSCs with two different interstimulus intervals (40 and 60 ms) for EAC3I-containing MSNs versus all controls. (WT: n = 9; tTA: n = 6; NON EGFP: n = 9; EGFP: n = 10; 40 ISI p = 0.38, 60 ISI p = 0.27). (D) Baclofen increases the CV of EPSCs. Coefficient of variation (CV = SD/Mean) change of EPSCs from before, during and after application of baclofen for EAC3I-containing and EAC3I-lacking MSNs (NON EGFP: n = 6; EGFP: n = 5; p = 0.95). (E) Baclofen increases the PPR. PPR (50 ms ISI) for EAC3I-containing and EAC3I-lacking MSNs before, during and after application of baclofen (NON EGFP: n = 6; EGFP: n = 5; p = 0.48). (F) Baclofen decreases sEPSC frequency. Plot of normalized sEPSC frequency post 10 μM Baclofen compared to baseline for EAC3I-containing and EAC3I-lacking MSNs (NON EGFP: n = 6; EGFP: n = 5; p = 0.96). Note: All MSNs held at −70 mV during recordings.

doi:10.1371/journal.pone.0045323.g003

Figure 4. Dorsal lateral striatum MSN CaMKII inhibition does not alter the level of glutamate at the cleft. (A) Normalized average NMDAR-mediated EPSC Charge (AUC) measured with 0.1 Hz stimulation in the presence of 10 μM Mk-801 over time for EAC3I-containing and EAC3I-lacking MSNs. (B) The rate of NMDA-mediated EPSC decay is best fit with a single exponential decay function. The time constant (tau) in seconds was not significantly different between groups (NON EGFP: n = 6; EGFP: n = 5; p = 0.65). All neurons held at −70 mV to relieve NMDAR-dependent voltage blockade by magnesium.

doi:10.1371/journal.pone.0045323.g004
frequency and amplitude in adult GluA1 KO versus control mice in the dorsal lateral striatum. We found that the loss of the GluA1 receptor also led to a significant reduction in sEPSC frequency (in Hz, control 3.2±0.8; GluA1KO 1.4±0.3) [U (31) = 66; p = 0.0133; Figure 6A, 6B], but not sEPSC amplitude (in pA, control 18.3±0.5; GluA1KO 18.1±0.4) [t (31) = 0.3576; p = N.S.; Figure 6A, 6C]. The similarity in synaptic outcomes of the GluA1 KO and EAC3I expression reinforces the idea that a common pathway has been affected.

MSN CaMKII inhibition leads to enhanced intrinsic excitability

To further examine the impact of CaMKII inhibition on physiological responses of dorsal striatal MSNs, we next examined excitatory drive and excitability of these cells under current clamp conditions. As expected from our voltage clamp experiments with sEPSCs, we also observed a robust decrease in the frequency of sEPSPs in the CaMKII inhibited cells versus control neurons in current clamp (in Hz, Wt 3.18±0.29; tTA 3.09±0.06; NON EGFP 3.04±0.33; EGFP 1.78±0.18) [F (3, 19) = 4.704; p = 0.0154; Figure 7A, 7C]. Surprisingly, however, we also observed a significant increase in sEPSP amplitude in the CaMKII-inhibited cells versus controls (in nV, Wt 0.48±0.05; tTA 0.47±0.10; NON EGFP 0.55±0.05; EGFP 0.77±0.09) [F (3, 19) = 3.605; p = 0.0367; Figure 7A, 7D]. As similar effects were not observed with sEPSC amplitudes, this suggested a change in excitability of EAC3I neurons. In order to further test this idea we measured basal intrinsic excitability. EGFP cells possessed a significantly more depolarized resting membrane potential (in mV, Wt −86.30±0.50; tTA −85.61±0.50; NON EGFP −85.52±0.38; EGFP −83.61±0.68) [H (3, 78) = 8.588; p = 0.0353; Figure 7E] and had significantly increased input resistance compared to control cells (in MΩ, Wt 75.85±9.90; tTA 91.98±6.22; NON EGFP 70.48±5.54; EGFP 122.65±13.81) [H (3, 79) = 19.89; p<0.0002; Figure 7F]. This suggests that CaMKII inhibition moves the resting membrane potential closer to firing threshold and increases membrane resistance to enhance the propagation of depolarizing current from distal MSN dendrites. Next we examined the voltage responses to differing current injections. While injecting minimal current to maintain resting membrane potential at −85 mV, a series of hyperpolarizing and depolarizing current injections were given in 20 pA steps. The threshold for 1st AP or rheobase current injection was significantly lower in the CaMKII inhibited MSNs versus control (in nV, Wt 357±32; tTA 285±28; NON EGFP 357±30; EGFP 194±17) [F (3, 79) = 9.393; p<0.0001; Figure 7G]. The firing threshold was not significantly different amongst groups (in nV, Wt −36.4±1.3; tTA −35.3±1.5; NON EGFP −33.4±0.8; EGFP −37.0±0.9) [F (3, 78) = 2.516; p = 0.0649], suggesting that input resistance changes are a major contributor to changes in rheobase. Also CaMKII inhibited cells exhibited increased spiking over a range of suprathreshold current injections [F (3,60) = 5.425; p = 0.0023; Figure 7H] versus control, reflecting a decrease in the interspike interval. Taken together, these data show that CaMKII inhibition enhances the intrinsic excitability of MSNs.

Discussion

We present converging lines of evidence that dorsal striatal MSN CaMKII inhibition decreases functional synapse number and increases intrinsic excitability. Inhibition of CaMKII in MSNs...
leads to a decrease in sEPSC frequency, without a change in release probability, glutamate levels at the synaptic cleft or dendritic spine density. These observations are consistent with a decrease in the number of functional synapses. In addition to changes in excitatory transmission, inhibition of CaMKII leads to an enhancement of MSN intrinsic excitability. These data suggest that CaMKII coordinates opposing regulation of excitatory transmission and intrinsic excitability in MSNs, serving as a cellular rheostat.

CaMKII inhibitors such as KN62 and KN93 have been useful tools in probing CaMKII functions, but these drugs also inhibit voltage-gated K⁺ and Ca²⁺ channels [77,78], and do not inhibit the autonomous activity of Thr286-autophosphorylated CaMKII [79,80]. In addition, in dendritic spines where the concentration of calmodulin and CaMKII are extremely high (~100 μM) [81,82], KN-62 (10 μM) only partially decreases CaMKII activity [18]. The EAC3I peptide we used inhibits all isoforms of CaMKII, including CaM-stimulated and autonomous activity, with low micromolar potency [52,56,83]. EAC3-I is 100-fold selective for CaMKII over protein kinase C, CaM Kinase I or CaM kinase IV [52,54]. The AC3-I peptide sequence differs from another highly selective CaMKII-inhibitor, AIP, by only one amino acid residue [55]. It is also important to consider the localization of CaMKII inhibition when interpreting these results. CaMKII is highly expressed in dopamine terminals, which densely innervate the striatum, where it stimulates dopamine efflux via the dopamine transporter in the presence of amphetamine [51]. In addition, CaMKII is present in glutamatergic projections, which form the presynaptic terminal onto MSN spines and dendrites [33,51], where it may modulate release events [39,43,44,45]. Our transgenic strategy resulted in the selective expression of the CaMKII inhibitor in the postsynaptic MSN, where it cannot directly affect the function of the glutamatergic and dopaminergic terminals, consistent with the lack of change in glutamate release parameters in EAC3I MSNs (Figures 3, 4).

We demonstrated that CaMKII inhibition decreases s/mEPSC frequency with no changes in presynaptic function. The lack of a bimodal distribution in the s/mEPSC frequency data suggests that CaMKII inhibition similarly affects both direct and indirect pathway MSNs. Changes in s/mEPSC frequency are traditionally interpreted as alterations in presynaptic quantal content; the product of changes in release probability or synapse number. However, multiple lines of evidence suggest that presynaptic function is unaltered. Together these data suggest that CaMKII inhibition decreases functional synapse number. One possibility is that CaMKII inhibition produces a loss of functional synaptic

Figure 6. GluA1KO mice mimic the EAC3I mice decrease in sEPSC frequency. (A) Example traces of sEPSCs collected from dorsal lateral striatum MSNs in Wt (top) and GluA1KO (bottom). Scale bars 0.5 sec, 30 pA (Control: n = 15; GluA1KO: n = 18; p = 0.013). (B) (left) Average sEPSC frequency in GluA1KO versus controls. (right) Cumulative probability graph of inter-event interval. (C) (left) Average sEPSC amplitude in GluA1KO versus controls. (right) Cumulative probability graph of amplitude (Control: n = 15; GluA1KO: n = 18; p = 0.72). * P < 0.05; error bars represent SEM. All MSNs were held at −70 mV.

doi:10.1371/journal.pone.0045323.g006
connections. Alternatively, there could be an increase in the number of silent synapses which contain NMDARs but no AMPARs and are typically abundant early in development [84,85,86,87,88,89]. A further possibility is that CaMKII inhibition could increase the numbers of silent modules of synapses or increase the number of AMPAR-lacking subregions of the synapse due to local nature of basal synaptic transmission [90,91]. In the hippocampus, silent synapses can be unsilenced following NMDAR activation by the introduction of new AMPARs to the synapse, underlying a common mechanism of LTP of synaptic glutamatergic transmission [26,27,92,93]. Previous research has suggested a direct role for CaMKII in the unsilencing of synapses in the hippocampus [94,95,96,97]. Additionally, CaMKII is required for the formation of new synapses and/or morphological growth following hippocampal LTP induction [18,98,99,100].

Striatal CaMKII inhibition did not alter dendritic spine density, suggesting that the decrease in s/mEPSC frequency could best be explained by some spines lacking active presynaptic terminals or increased numbers of silent synapses. However, the significant increase in the input resistance of EAC3I-positive MSNs should enhance sampling of mEPSCs from more distal dendritic sites, potentially increasing s/mEPSC frequency. These data together suggest that decreases in s/mEPSC frequency in EAC3-I MSNs are potentially underestimated. Alternatively, some of these effects may be due to decreased dendritic length and complexity seen in EAC3I-positive MSNs. However, it is not clear whether distal MSN synapses are sampled in our s/mEPSC analyses due to cable filtering effects previously reported [101]. Hippocampal CaMKII has been shown to modulate dendritic length and branching as well as synapse number [70]. These results suggest that CaMKII plays important roles in modeling MSN dendritic morphology.

Striatal CaMKII inhibition did not alter dendritic spine density, suggesting that the decrease in s/mEPSC frequency could best be explained by some spines lacking active presynaptic terminals or increased numbers of silent synapses. However, the significant increase in the input resistance of EAC3I-positive MSNs should enhance sampling of mEPSCs from more distal dendritic sites, potentially increasing s/mEPSC frequency. These data together suggest that decreases in s/mEPSC frequency in EAC3-I MSNs are potentially underestimated. Alternatively, some of these effects may be due to decreased dendritic length and complexity seen in EAC3I-positive MSNs. However, it is not clear whether distal MSN synapses are sampled in our s/mEPSC analyses due to cable filtering effects previously reported [101]. Hippocampal CaMKII has been shown to modulate dendritic length and branching as well as synapse number [70]. These results suggest that CaMKII plays important roles in modeling MSN dendritic morphology. The CaMKII alpha promoter fragment that drives EAC3I expression reportedly turns on around P5 [102,103,104,105]. This would lead to inhibition of CaMKII in early postnatal development and continuing into adulthood. The effects of this longer term genetic CaMKII inhibition contrasts with the typically minimal effects of acute, short term application of a related CaMKII inhibitor peptide, AIP, on basal glutamatergic transmission in the CA1 and CA3 region of the hippocampus [106,107,108,109]. Conversely, expression of CaMKII inhibitor

Figure 7. CaMKII inhibition enhances MSN intrinsic excitability. (A) Traces of EAC3I-lacking (NON EGFP, black) and EAC3I-containing MSNs (EGFP, green) sEPSPs recorded at −85 mV. Scale bars 0.6 mV, 200 ms. (B) Traces of EAC3I-lacking (black) and EAC3I-containing MSNs (green) with 20 pA hyperpolarizing and depolarizing current injections (−120 pA to +100 pA above AP threshold, 20 pA steps). Scale bars 200 ms, 20 mV. (C) Average sEPSP frequency in EAC3I-containing MSNs versus controls (Wt: n = 4; tTA: n = 4; NON EGFP: n = 9; versus EGFP: n = 6; p = 0.015). (D) Average sEPSP amplitude (current clamped at −85 mV) in EAC3I-containing MSNs versus controls (Wt: n = 4; tTA: n = 4; NON EGFP: n = 9; versus EGFP: n = 6; p = 0.037). (E) Resting membrane potential (RMP) (mV) of EAC3I-containing and control MSNs (Wt: n = 18; tTA: n = 15; NON EGFP: n = 22; versus EGFP: n = 24; p = 0.0043). (F) Input resistance of EAC3I-containing and control MSNs (Wt: n = 18; tTA: n = 15; NON EGFP: n = 22; versus EGFP: n = 24; p = 0.0002). (G) Rheobase current injection or current injection to reach 1st AP in EAC3I-containing and control MSNs (Wt: n = 18; tTA: n = 15; NON EGFP: n = 22; versus EGFP: n = 24; p < 0.0001). (H) Firing frequency (Hz) after 4 sweeps (20 pA steps) following threshold firing in EAC3I-containing and control MSNs (Wt: n = 18; tTA: n = 15; NON EGFP: n = 22; versus EGFP: n = 24; p = 0.0023). *P < 0.05; **P < 0.01; ***P < 0.001; error bars represent SEM. doi:10.1371/journal.pone.0045323.g007
peptides CaMIIIN or AIP over 2–6 days reduced hippocampal CA1 AMPAR-mediated, but not NMDAR-mediated EPSCs [110]. Another report suggests a CaMII inhibition peptide, CN19, persistently decreased hippocampal CA1 field EPSPs or EPSCs amplitudes at higher concentrations disrupting the CaMII/NMDAR complex [111]. These data suggest that disruption of the CaMII/NMDAR complex, a complex that increases following strong synaptic stimulation [112] and is necessary for LTP [113,114], may offer an alternative mechanism underlying our observed effects.

Endogenous CaMII levels peak around 3 weeks postnatally, which is a crucial time for synaptogenesis and synapse maturation [104,105,115]. The apparent decrease in functional synaptic connections in CaMII inhibited MSNs in adulthood may have four possible explanations: 1) CaMII activity is necessary for the normal unsilencing of synapses in the adult; 2) Ongoing CaMII activity is required to maintain functional synapses; or 3) CaMII is needed early in synaptogenesis to turn initially silent synapses into functional ones; or 4) the CaMII-mediated decrease in dendritic length may underlie the reduction in total synapse number. The decrease in sEPSC frequency in EAC3I MSNs was detected as early as three weeks postnatally, suggesting a large proportion of synapses were never unsilenced or perhaps never formed. In the hippocampus both electrophysiological and anatomical studies at light and electron microscopic levels suggest that in the first few weeks of life many synapses start as NMDAR-only synapses or silent synapses [116,117,118,119,120]. Synapse unsilencing involving the trafficking of new AMPARs (GluA4-containing) to the synapse in early postnatal development is dependent on activity, but is independent of CaMII [121,122]. Instead, PKA plays an important role early in postnatal development (<P9) in plasticity in the hippocampus being necessary and sufficient for GluA4 incorporation, but requiring additional CaMII activity for GluA1 receptor incorporation [122,123,124]. These data suggest that the similar synaptic phenotypes of GluA1KO and EAC3I mice arise from disruption of a common mechanism. However, it is interesting that the phenotype of the EAC3I cells is also virtually identical to that recently reported for MSNs in SAPAP3 knockout mice [7,125]. Intriguingly, SAPAP3 may be phosphorylated by CaMII, possibly assisting in synaptic targeting of GluA1R [126]. Thus, it will be important for future studies to directly identify downstream MSN proteins regulated by CaMII.

It is also possible that differences in the relative innervation of MSNs by cortical and thalamic inputs impacts the synaptic phenotypes. Indeed, differences in release probability have been observed between the two inputs [127,128,129]. Our measures of sEPSC and mEPSC frequency are likely comprised of both cortical and thalamic-mediated glutamate release, yet our data do not rule out the possibility that inhibition of MSN CaMII may have a greater influence on one of these excitatory synapses over the other.

CaMII inhibition also leads to alterations in intrinsic excitability that may serve to broadly counteract the reduced s/ mEPSC frequency. Although we expected a decrease in sEPSC frequency in current clamp based on the sEPSC results, we observed significantly larger sEPSC amplitudes. This is likely due to enhanced intrinsic excitability. In CaMII-inhibited neurons we observed more depolarized resting membrane potentials, increased membrane resistance, decreased rheobase current injection, and increased firing frequency. Autonomous activity CaMII has been shown to suppress neuronal excitability by increasing cell-surface expression of an A-type K+ channel, Kv4.2, via phosphorylation [90,130,131]. In addition, CaMII inhibition in medial vestibular nucleus neurons increased intrinsic excitability via a reduction in BK-type calcium activated potassium currents [132]. Changes in Kv4.2 or BK activity following CaMII inhibition could account for the differences in firing that we observed in EAC3I cells. However, modulation of Kir 2 channels may be responsible for the changes in input resistance and resting membrane potential [133]. A recent study showed that acute CaMII inhibition in cortical cultures leads to increased excitability, but also increased cell death [134]. We did not note increased cell death, nor did membrane properties hint at unhealthy EAC3I-expressing cells. The differences in these studies may be attributed to the fact that MSNs are GABAergic cells bypassing potential excitotoxicity vulnerabilities seen with recurrent excitatory connections in the cortex. Alternatively, cortical cultures—which are often more excitable - may have a more difficult time regulating extracellular glutamate levels, something that is not as problematic in ex vivo slice preparations.

The opposing regulation of excitatory transmission and excitability observed in these studies suggests that CaMII may serve as a molecular fulcrum to counterbalance changes in enhanced excitatory input with decreases in excitatory output. It is important to note in the present dataset we cannot rule out that possibility that one of these adaptations is compensatory to the other, rather than both being directly initiated by CaMII inhibition. Regardless, this likely has important implications for the modulation of basal ganglia circuitry underlying habit learning, addiction and neurodegenerative disease. CaMII plays a role in setting the number of functional synapses and therefore may provide a substrate for experience dependent plasticity in the striatum. Dorsal striatal CaMII may be crucial early in postnatal development as well as in adulthood entraining new motor repertoires and refining synaptic connections as those motor skills are refined into habits later in life. With the inhibition of CaMII leading to a decrease in the number of functional contacts, CaMII may function in the dendritic and synaptic maturation processes, from nascent filopodia to mature dendritic spine [18,99], or alternatively be important in maintaining existing synaptic connections. Further investigation will be needed to determine the precise role of CaMII in striatal synaptic maturation.

Supporting Information

Figure S1 Striatal interneuron markers do not colocalize with EAC3I peptide. (A) 20× confocal image of dorsal lateral striatum from an EAC3I mouse of endogenous EGFP expression (green) and striatal ChAT immunopositive interneurons (red, 0/70 ChAT positive neurons contained EGFP). Scale bar 100 μm, inset 50 μm. (B) Like A, but striatal parvalbumin immunopositive interneurons labeled (red, 0/37 parvalbumin positive neurons contained EGFP). Scale bar 100 μm, inset 50 μm. (C) Like A, but striatal calretinin immunopositive interneurons labeled (red, 0/22 calretinin positive neurons contained EGFP). Scale bar 100 μm, inset 50 μm. (D) Like A, but striatal calretinin immunopositive interneurons labeled (red, 0/15 calretinin positive neurons contained EGFP). Scale bar 100 μm, inset 50 μm. (TIF)

Acknowledgments

We thank the Vanderbilt Cell Imaging Shared Resource for help in acquisition of confocal images. We thank Drs. Sachin Patel and Brian Shoenes, along with members of the Winder lab for providing feedback on a previous version of the manuscript. We thank Pete Vollbrecht for help with dendritic spine analysis.
Author Contributions

Conceived and designed the experiments: JRK TAD YRD JCG DWG. Performed the experiments: JRK BNM TLK HDW RTM. Analyzed the data: JRK BNM TLK HDW RTM. Contributed reagents/materials/analysis tools: AJR MEA AYD DML. Wrote the paper: J RK JCG DWG.

References

1. Yin HH, Knowlton BJ (2006) The role of the basal ganglia in habit formation. Nat Rev Neurosci 7: 464–476.
2. Jenner P (2008) Molecular mechanisms of L-DOPA-induced dyskinasia. Nat Rev Neurosci 9: 665–677.
3. Kreitzer AC, Malenka RC (2008) Striatal plasticity and basal ganglia circuit function. Neuon 69: 543–554.
4. Milnerwood AJ, Raymond LA (2010) Early synaptic pathophysiology in neurodegeneration: insights from Huntington’s disease. Trends Neurosci 33: 513–523.
5. Redgrave P, Rodriguez M, Smith Y, Rodriguez-Oroz MC, Lehericy S, et al. (2010) Goal-directed and habitual control in the basal ganglia: implications for Parkinson’s disease. Nat Rev Neurosci 11: 760–772.
6. Luscher T, Malenka RC (2011) Drug-evoked synaptic plasticity in addiction: from molecular changes to circuit remodeling. Neuon 69: 650–663.
7. Wan Y, Feng G, Calakos N (2011) Sapat3 deletion causes mGluR5-dependent silencing of AMPAR synapses. J Neurosci 31: 16605–16619.
8. Yang XW, Lu XH (2011) Molecular and cellular basis of obsessive-compulsive disorder: behaviors emerging from mouse models. Curr Opin Neurol 24: 114–118.
9. Erondu NE, Kennedy MB (1985) Regional distribution of type II Ca2+/calmodulin-dependent protein kinase in rat brain. J Neurosci 5: 3270–3277.
10. Lissman J, Schulman H, Cline H (2002) The molecular basis of CaMKII function in synaptic and behavioural memory. Nat Rev Neurosci 3: 175–190.
11. Fujimaki K, Goto S, Miyamoto E (1980) Immunohistochemical localization of Ca2+/calmodulin-dependent protein kinase II in rat brain and various tissues. Brain Res 193: 1070–1078.
12. Cheng D, Hoogendoorn CC, Rus J, Ramn E, Schлага MA, et al. (2006) Relative and absolute quantification of postsynaptic density protein isoforms isolated from rat forebrain and cerebellum. Mol Cell Proteomics 3: 1158–1170.
13. Basbaum AJ 2nd, Strack S, Colbran RJ (2012) Age-dependent targeting of CaMKII in single dendritic spines during long-term potentiation. Nature 458: 3026–3027.
14. Lee SJ, Escobedo-Lozoya Y, Szatmari EM, Yasuda R (2009) Activation of CaMKII in single dendritic spines during long-term potentiation. Nature 458: 299–304.
15. Wan Y, Feng G, Calakos N (2011) Sapap3 deletion causes mGluR5-dependent silencing of AMPAR synapses in thalamus and cerebral cortex. Proc Natl Acad Sci U S A 93: 7332–7336.
16. Jones EG, Huntley GW, Benson DL (1994) Alpha calcium/calmodulin-dependent protein kinase II selectively expressed in a subpopulation of excitatory neurones in monkey sensory-motor cortex: comparison with GAD-67 expression. J Neurosci 14: 611–629.
17. Picconi B, Gardoni F, Centonze D, Manieri D, Cenci MA, et al. (2004) Aluminium Ca2+/calmodulin-dependent protein kinase II function mediates synaptic and motor deficits in experimental parkinsonism. J Parkinsons Dis 24: 5291–5293.
18. Wilgen BJ, Law M, Osmond S, Mayford M, Balleine BW (2007) The influence of Pavlovian cues on instrumental performance is mediated by CaMKII activity in the striatum. Eur J Neurosci 25: 2491–2497.
19. Stein IS, Hehl JW (2010) CaMKII hunkers down on the muscarinic M4 receptor to help curb cocaine-induced hyperlocomotion. EMBO J 29: 1943–1953.
20. Stefani G, Onofri F, Valtorta F, Vazzaro C, Greengard P, et al. (1997) Kinetic analysis of the phosphorylation-dependent interactions of synapsin I with rat brain synaptic vesicles. J Physiol 504 (Pt 3): 501–515.
21. Chu P, Greengard P, Ryo TA (2001) Synapsin dispersion and clustering during synaptic activity. Nat Neurosci 4: 1187–1193.
22. Waxham MN, Malenka RC, Kelly PT, Maud MK (1993) Calcium/calmodulin-dependent protein kinase II regulates hippocampal synaptic transmission. Brain Res 609: 1–8.
23. Lin JW, Sugimori M, Linnas RR, McCaig DL, Greengard P (1990) Effects of synapsin I and calcium/calmodulin-dependent protein kinase II on spontaneous neurotransmitter release in the squid giant synapse. Proc Natl Acad Sci U S A 87: 2527–2531.
24. Linas R, McCaig DL, Leonard SS, Sugimori M, Greengard P (1995) Intraterminal injection of synapsin I or calcium/calmodulin-dependent protein kinase II alters neurotransmitter release at the squid giant synapse. Proc Natl Acad Sci U S A 92: 3003–3007.
25. Hjortj MR, van Woerden GM, Tyler WJ, Giese KP, Silva AJ, et al. (2007) Kinase activity is not required for alphaCaMKII-dependent presynaptic plasticity at CA3-CA1 synapses. Nat Neurosci 10: 1125–1127.
26. Jiang X, Laumert-Mied NJ, Watari H, Westonbroek RE, Scheuer T, et al. (2008) Modulation of CaV2.1 channels by Ca2+/calmodulin-dependent protein kinase II bound to the C-terminal domain. Proc Natl Acad Sci U S A 105: 341–346.
27. Elgavera Y, Fedrov NB, Bonen S, Choi ES, Elgersma M, et al. (2002) Inhibitory autophosphorylation of CaMKII controls PSD association, plasticity, and learning. Neuon 36: 493–505.
28. Wagner S, Dykhova N, Rasenack EC, Jacobshagen C, Fabricz L, et al. (2006) Ca2+/calmodulin-dependent protein kinase II regulates cardiac Na+ channels. J Clin Invest 116: 3127–3130.
29. Yamashita T, Katana H, Fujisawa H (1981) A new activator protein that increases Ca2+-, calmodulin-dependent protein kinase activity. Biochem Biophys Res Commun 74: 394–399.
30. Carlier E, Dargent B, De Waard M, Courraud F (2004) A Na+ channel regulation by calmodulin kinase II in rat cerebellar granule cells. Biochem Biophys Res Commun 274: 394–399.
31. Benke TA, Luthi A, Isaac JT, Collingridge GL (1999) Modulation of AMPA receptor unitary conductance by synaptic activity. Nature 393: 793–797.
32. Strack S, McNeill RB, Colbran RJ (2000) Mechanism and regulation of calcium/calmodulin-dependent protein kinase II targeting to the NMDA receptor subunit of the N-methyl-D-aspartate receptor. J Biol Chem 275: 23782–23786.
33. Hayashi Y, Shi SH, Esteban JA, Piccini A, Ponce JC, et al. (2000) Driving AMPA receptors into synapses by LTP and CaMKII requirement for GluR1 and PDEF domain interaction. Science 287: 2282–2287.
34. Shi SH, Hayashi Y, Petralia RS, Zaman SH, Wenthol RJ, et al. (1999) Rapid spine redistribution and delivery of AMPA receptors after synaptic NMDA receptor activation. Science 284: 1611–1616.
51. Fog JU, Kshobhoiue H, Hol M, Ovens WA, Vaegter CB, et al. (2006) Calmodulin kinase II interacts with the dopamine transporter C terminus to regulate amphetamine-induced reverse transport. Neuron 51: 417–429.

52. Braun AP, Schulman H (1995) A non-selective cation current activated via the multifunctional Ca2+/calmodulin-dependent protein kinase in human epithelial cells. J Physiol 481 (Pt 1): 37–55.

53. Wu Y, Temple J, Zhang R, Dzhura I, Zhang W, et al. (2002) Calmodulin kinase II and arrhythmias in a mouse model of cardiac hypertrophy. Circulation 106: 1280–1285.

54. Patel R, Holt M, Philippa R, Moss S, Schulman H, et al. (2004) Calcium-, calmodulin-dependent phosphorylation and activation of human G92-C at the G2/M phase transition in Hela cells. J Biol Chem 274: 7956–7968.

55. Vekin RS, Davies KD, O’Leary H, Post JD, Bayer KU (2007) Dual mechanism of a natural CaMKII inhibitor. Mol Biol Cell 18: 5024–5033.

56. Zhang R, Khoos MS, Wu Y, Yang Y, Grueter CE, et al. (2005) Calmodulin kinase II inhibition protects against structural heart disease. Nat Med 11: 409–417.

57. Zamanillo D, Spergel R, Hvally O, Jensen V, Banaheev N, et al. (1999) Importance of AMPA receptors for hippocampal synaptic plasticity but not for spatial learning. Science 294: 1085–1081.

58. Kawaguchi Y, Wilson CJ, Emerson PC (1989) Intracellular recording of identified neostriatal patch and matrix spiny cells in a slice preparation preserving cortical inputs. J Neurophysiol 62: 1052–1068.

59. Mayford M, Bach ME, Huang YY, Wang I, Hawkins RD, et al. (1996) Control of memory formation through regulated expression of a CaMKII transgene. Science 274: 1678–1683.

60. Kaufmann WL, Kocman I, Agrawal V, Rahn BP, Besser D, et al. (2008) Homogeneity and persistence of transgene expression by omitting antibiotic selection in cell line isolation. Nucleic Acids Res 36: e111.

61. Bejar R, Yasuda R, Krugers H, Hood K, Mayford M (2002) Transgenic calmodulin-dependent protein kinase II activation: dose-dependent effects on synaptic plasticity, learning, and memory. J Neurosci 22: 5719–5726.

62. Zucker RS, Regehr WG (2002) Short-term synaptic plasticity. Annu Rev Physiol 64: 355–405.

63. Lei S, McIlain CJ (2003) GABA B receptor modulation of excitatory and inhibitory synaptic transmission onto rat CA3 hippocampal interneurons. J Physiol 549: 439–453.

64. Huettner JE, Bean BP (1988) Block of N-methyl-D-aspartate-activated current by the anticonvulsant MK-801: selective binding to open channels. Proc Natl Acad Sci U S A 85: 1307–1311.

65. Day M, Wang A, Ding J, An X, Ingham CA, et al. (2006) Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models. Nat Neurosci 9: 231–259.

66. Verpelli C, Dvorotkova E, Viciadoni C, Rossi F, Chiappalone M, et al. (2011) Importance of Shank3 protein in regulating metabotropic glutamate receptor 5 (mGluR5) expression and signaling at synapses. J Biol Chem 286: 34383–34390.

67. Lu Y, Zha XM, Kim EY, Schachtele S, Dailey ME, et al. (2011) A kinase anchor protein 150 (AKAP150)-associated protein kinase A limits dendritic spine density. J Biol Chem 286: 26496–26506.

68. Fu WY, Chen Y, Sahin M, Zhao XS, Shi L, et al. (2007) Cdk5 regulates EphA-mediated dendritic spine retraction through an ephexin1-dependent mechanism. J Neurosci 27: 7958–7968.

69. Ding JB, Oh WJ, Sabatini BL, Gu C (2012) Semaphorin 3E-Plexin-D1 signaling controls pathway-specific synapse formation in the striatum. Nat Neurosci 15: 213–223.

70. Tink GC, Bayer KU, Myers JW, Ferreralle JE, Jr, Schulman H, et al. (2003) Selective regulation of neurite extension and synapse formation by the beta but not the alpha isoform of CaMKII. Neuron 39: 293–297.

71. Mack V, Banaheev N, Kaiser KM, Rozov A, Jensen V, et al. (2001) Conditional restoration of hippocampal synaptic plasticity in GluA deficient mice. Science 292: 2501–2504.

72. Bannerman DM, Deacon RM, Brady S, Bruce A, Spergel R, et al. (2004) A comparison of GluA-A deficient and wild-type mice on a test battery assessing sensorimotor, affective, and cognitive behaviors. Behav Neurosci 118: 643–647.

73. Wiedohne LM, Owens WA, Horton RE, Feyder M, Karlsson RM, et al. (2008) Mice lacking the AMPA GluR1 receptor exhibit striatal hyperdopaminergia and ‘schizophrenia-related’ behaviors. Mol Psychiatry 13: 631–640.

74. Schmitz WR, Spergel R, Mack V, Duff RW, Serbijn PH, et al. (2005) Restoration of spatial working memory by genetic rescue of GluA-A deficient mice. Science 292: 2501–2504.

75. Reisel D, Bannerman DM, Schmitt WB, Deacon RM, Flint J, et al. (2002) Spatial memory dissociations in mice lacking GluR1. Nat Neurosci 5: 868–873.

76. Zhou R, Holmes A, Du J, Malkesman O, Yuan P, et al. (2009) Genome-wide gene expression profiling in GluK1 knockout mice: key role of the calcium signaling pathway in glutamatergically mediated hippocampal transmission. J Biol Chem 284: 21719–21726.

77. Li G, Helaka H, Wollerme CB (1992) Inhibition of voltage-gated Ca2+ channels and insulin secretion in HIT cells by the Ca2+/calmodulin-dependent protein kinase II inhibitor KN-93: comparison with antagonists of calmodulin-dependent protein kinases. Mol Pharmacol 42: 4709–4703.

78. Ledoux J, Chartier D, Leblanc N (1999) Inhibitors of calmodulin-dependent protein kinase are nonselective blockers of voltage-dependent K+ channels in vascular myocytes. J Pharmacol Exp Ther 290: 1165–1174.
108. Shen G, Van Sickle BJ, Tietz EI (2010) Calcium/calmodulin-dependent protein kinase II mediates hippocampal glutamatergic plasticity during benzodiazepine withdrawal. Neuropsychopharmacology 35: 1897–1909.

109. Buard I, Coudrap SJ, Freund RK, Lee YS, Dell’Acqua ML, et al. (2010) CaMKII “autonomy” is required for initiating but not for maintaining neuronal long-term information storage. J Neurosci 30: 8214–8220.

110. Goold CP, Nicoll RA (2010) Single-cell optogenetic excitation drives homeostatic synaptic depression. Neuron 68: 512–528.

111. Sanhueza M, Fernandez-Villalobos G, Stein IS, Kasumova G, Zhang P, et al. (2011) Role of the CaMKII/NMDA receptor complex in the maintenance of synaptic strength. J Neurosci 31: 9170–9178.

112. Leonard AS, Lim IA, Hemsworth DE, Horne MC, Hell JW (1999) Calcium/calmodulin-dependent protein kinase II is associated with the N-methyl-D-aspartate receptor. Proc Natl Acad Sci U S A 96: 3239–3244.

113. Barria A, Malinow R (2005) NMDA receptor subunit composition controls synaptic plasticity by regulating binding to CaMKII. Neuron 48: 289–301.

114. Zhou Y, Takahashi E, Li W, Hall A, Witgen B, et al. (2007) Interactions between the NR2B receptor and CaMKII modulate synaptic plasticity and spatial learning. J Neurosci 27: 13043–13053.

115. Hanley RM, Means AR, Oto T, Kemp BE, Burgin KE, et al. (1987) Functional analysis of a complementary DNA for the 50-kilodalton subunit of calmodulin kinase II. Science 237: 293–297.

116. Rao A, Craig AM (1997) Activity regulates the synaptic localization of the NMDA receptor in hippocampal neurons. Neuron 19: 801–812.

117. Gomperts SN, Rao A, Craig AM, Malenka RC, Nicoll RA (1998) Postsynaptically silent synapses in single neuron cultures. Neuron 21: 1443–1451.

118. Petralia RS, Esteban JA, Wang YX, Partridge JG, Zhao HM, et al. (1999) Selective acquisition of AMPA receptors over postnatal development suggests a molecular basis for silent synapses. Nat Neurosci 2: 31–36.

119. NuSSer Z, Lujan R, Lauhe G, Roberts JD, Molnar E, et al. (1998) Cell type and pathway dependence of synaptic AMPA receptor number and variability in the hippocampus. Neuron 21: 545–559.

120. Takami Y, Ramirez-Leon V, Lauhe P, Rinvik E, Ottersen OP (1999) Different modes of expression of AMPA and NMDA receptors in hippocampal synapses. Nat Neurosci 2: 618–624.

121. Zhu JJ, Esteban JA, Hayashi Y, Malinow R (2000) Postnatal synaptic potentiation: delivery of GluR4-containing AMPA receptors by spontaneous activity. Nat Neurosci 3: 1098–1106.

122. Esteban JA, Shi SH, Wilson C, Nuriya M, Huganir RL, et al. (2003) PKA phosphorylation of AMPA receptor subunits controls synaptic trafficking underlying plasticity. Nat Neurosci 6: 136–143.

123. Man HY, Sekine-Azawa Y, Huganir RL (2007) Regulation of (alpha)-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor trafficking through PKA phosphorylation of the Glu receptor 1 subunit. Proc Natl Acad Sci U S A 104: 3579–3584.

124. Yasuda H, Barth AL, Stellwagen D, Malenka RC (2003) A developmental switch in the signaling cascades for LTP induction. Nat Neurosci 6: 15–16.

125. Chen M, Wan Y, Ade K, Ting J, Feng G, et al. (2011) Sapep3 deletion anomalously activates short-term endocannabinoid-mediated synaptic plasticity. J Neurosci 31: 9563–9573.

126. Dosemeci A, Jaffe H (2010) Regulation of phosphorylation at the postsynaptic density during different activity states of Ca2+/calmodulin-dependent protein kinase II. Biochem Biophys Res Commun 391: 78–84.

127. Ding J, Peterson JD, Surmeier DJ (2008) Corticostriatal and thalamostriatal synapses have distinctive properties. J Neurosci 28: 6485–6492.

128. Ding JB, Guzman JN, Peterson JD, Goldberg JA, Surmeier DJ (2010) Thalamic gating of corticostriatal signaling by cholinergic interneurons. Neuron 67: 294–307.

129. Smeal RM, Gaspar RC, Keefe KA, Wiley JS (2007) A rat brain slice preparation for characterizing both thalamostriatal and corticothalamic afferents. J Neurosci Methods 159: 224–235.

130. Rooper J, Lorza C, Pongs O (1997) Frequency-dependent inactivation of mammalian A-type K+ channel KV1.4 regulated by Ca2+/calmodulin-dependent protein kinase. J Neurosci 17: 3379–3391.

131. Park D, Golman MJ, Hodge JJ, Budnik V, Griffith LC (2002) Regulation of neuronal excitability in Drosophila by constitutively active CaMKII. J Neurobiol 52: 24–42.

132. Nelson AB, Gittis AH, du Lac S (2005) Decreases in CaMKII activity trigger persistent potentiation of intrinsic excitability in spontaneously firing vestibular nucleus neurons. Neuron 46: 623–631.

133. Cazorla M, Shegda M, Ramesh B, Harrison NL, Kellendonk C (2012) Striatal D2 receptors regulate dendritic morphology of medium spiny neurons via Kir2 channels. J Neurosci 32: 2398–2409.

134. Ashpole NM, Song W, Brustovetsky T, Engleman EA, Brustovetsky N, et al. (2012) Calcium/calmodulin-dependent protein kinase II (CaMKII) inhibition induces neurotoxicity via dysregulation of glutamate/calcium signaling and hyperexcitability. J Biol Chem.